hrp0095p2-56 | Diabetes and Insulin | ESPE2022

Monogenic Diabetes (MODY) in Adolescents and Personalized Treatment.

Xu Xu , Volcotrub Egor , Ten Svetlana

Background: MODY can be mistaken for Diabetes type 1 or type 2.Objective: To evaluate genetic background in 22 patients presented with diabetes, negative islet cell antibodies, normal C-peptide and positive family history of diabetes. Genetic testing was done at Invitae laboratory and evaluated 28 genes for diagnosis of MODY.Results: Patients were divided into 2 groups: Group 1 wit...

hrp0095p2-64 | Diabetes and Insulin | ESPE2022

Diabetes Secondary to Glucokinase Gene Polymorphism with Obesity and Fluctuating Severity of Diabetes

Aljalily Sarraa , Xu Xu , Ten Svetlana

Case report: 14 yrs. old Hispanic girl was referred for evaluation of diabetes (Hb A1c 9.8 %) and morbid obesity BMI 36 kg/m2. She developed acanthosis nigricans, elevated triglycerides (TG) 1162 mg/dl, low HDL 34 mg/dl, fatty liver with elevated AST 84 U/l, ALT 103 U/L. The abdominal sonogram revealed significant hepatomegaly with moderate steatosis. Her islet cell AB were negative, C-peptide 3.11 ng/ml was normal. She has a strong family history of diabetes:...

hrp0097p1-553 | Pituitary, Neuroendocrinology and Puberty | ESPE2023

A 12-month, open-label, single-arm, phase 3 trial of the efficacy and safety of triptorelin 3-month formulation in Chinese children with central precocious puberty (CPP)

Luo Xiaoping , Zhang Cai , Yang Yu , Xu Xu , Cheng Xinran , Wei Haiyan , Wang Lanying , Huang Frank , Cabri Patrick

Background: CPP is commonly treated with triptorelin, a gonadotropin-releasing hormone (GnRH) analogue. It is available as 1-month and 3-month prolonged-release (PR) formulations, but only the former is approved for CPP in China. Overseas studies have proved the efficacy and safety of triptorelin 3-month PR formulation; this study evaluated efficacy and safety in Chinese children with CPP.Methods: In this 12-month, open-...